Argenx advances clinical development of efgartigimod

Argenx announced its plan to continue the development of efgartigimod to Phase 3 in adults with primary Sjogren’s disease, or SjD, following the analysis of topline data from the Phase 2 RHO study. Detailed results will be presented at a future medical meeting. The decision to advance the clinical development of efgartigimod in SjD was supported by the safety, efficacy and biomarker results from the study. The observed safety and tolerability profile was consistent with other clinical trials. Efficacy assessments showed a treatment effect across multiple clinical endpoints, which were also consistent with biomarker data.